Gilad Yahalom
Overview
Explore the profile of Gilad Yahalom including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
588
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Livneh V, Faust-Socher A, Cohen M, Schechter Y, Israel I, Eichel R, et al.
CNS Neurol Disord Drug Targets
. 2025 Jan;
PMID: 39838672
Background: Botulinum Toxin type A (BonTA) is the preferred treatment for Cervical Dystonia (CD). However, the success rate is often suboptimal. One of the reasons for treatment failure is the...
2.
Westenberger A, Skrahina V, Usnich T, Beetz C, Vollstedt E, Laabs B, et al.
Brain
. 2024 Aug;
147(8):2652-2667.
PMID: 39087914
Estimates of the spectrum and frequency of pathogenic variants in Parkinson's disease (PD) in different populations are currently limited and biased. Furthermore, although therapeutic modification of several genetic targets has...
3.
Skrahin A, Horowitz M, Istaiti M, Skrahina V, Lukas J, Yahalom G, et al.
Int J Mol Sci
. 2024 Jul;
25(13).
PMID: 39000225
-associated Parkinson's disease (-PD) is increasingly recognized as a distinct entity within the spectrum of parkinsonian disorders. This review explores the unique pathophysiological features, clinical progression, and genetic underpinnings that...
4.
Cohen M, Shechter Y, Eichel R, Yahalom G
Parkinsonism Relat Disord
. 2024 May;
124:106990.
PMID: 38735164
Background: Subjects carrying mutations in the GBA gene, whether in one or two alleles pose a risk to develop Parkinson's disease (PD). This type of GBA-related PD has usually a...
5.
Cohen M, Eichel R, Rajz G, Yahalom G
Isr Med Assoc J
. 2023 Jul;
25(7):456-461.
PMID: 37461169
Background: Little is known about phenotypical variations among ethnic groups in patients with Parkinson's disease (PD) in Israel. Clinical characteristics of non-Ashkenazi Jews (NAJ) are scantly described. Objectives: To describe...
6.
Yahalom G, Atlan E, Janah A, Dominko M, Israel I, Rajz G, et al.
Clin Neuropharmacol
. 2023 May;
46(3):89-94.
PMID: 37191561
Objectives: This is a case series and a review of the literature of therapeutic outcomes of botulinum toxin (BT) injections for anterocollis. Methods: Data collected included gender, age, age at...
7.
Gurevich T, Arkadir D, Badarny S, Benizri S, Cohen O, Djaldetti R, et al.
Front Aging Neurosci
. 2022 Nov;
14:1029824.
PMID: 36389061
Parkinson's disease (PD) is taking a staggering toll on healthcare systems worldwide, with the bulk of the expenditures invested in the late stages of the disease. Considering the rising life...
8.
Becker-Cohen M, Zimran A, Dinur T, Tiomkin M, Cozma C, Rolfs A, et al.
Int J Mol Sci
. 2022 Oct;
23(20).
PMID: 36293067
Carriers of GBA1 gene variants have a significant risk of developing Parkinson’s disease (PD). A cohort study of GBA carriers between 40−75 years of age was initiated to study the...
9.
Yahalom G, Janah A, Rajz G, Eichel R
Toxins (Basel)
. 2022 May;
14(5).
PMID: 35622608
The aim of this study was to show our therapeutic outcome of botulinum injection to the facial muscles and thereby to find the best therapeutic concept which should be embraced....
10.
Hassin-Baer S, Cohen O, Israeli-Korn S, Yahalom G, Benizri S, Sand D, et al.
PLoS One
. 2022 Jan;
17(1):e0261947.
PMID: 34995285
Objective: The purpose of this study is to explore the possibility of developing a biomarker that can discriminate early-stage Parkinson's disease from healthy brain function using electroencephalography (EEG) event-related potentials...